IgA Nephropathy (IgAN) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

IgA Nephropathy (IgAN) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033

Report Format: PDF+Excel | Report ID: SR112023A6739
Buy Now

The IgA nephropathy (IgAN) market has been comprehensively analyzed in IMARC's new report titled "IgA Nephropathy (IgAN) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033". IgA nephropathy (IgAN), commonly known as Berger's disease, is a rare autoimmune disorder affecting the kidneys. It is characterized by predominant IgA protein deposition and impairment of blood filtration in the blood channels of the kidneys. An untreated IgA nephropathy results in kidney failure. During the early phases of this illness, there may be no apparent signs or symptoms, and it may take years or even decades for the afflicted person to recognize them. However, when the symptoms appear, the patient will notice blood in the urine, which is known as hematuria. Hematuria might also indicate damaged glomeruli. Another indication of this disease is the presence of foamy urine, which is caused by high amounts of protein present in it and is termed albuminuria. The diagnosis of IgA nephropathy begins with the healthcare professional reviewing the patient's medical and family history and then conducting tests. These tests include a urine examination to check for the presence of protein or blood in the urine, a blood test to detect the levels of cholesterol, protein, and wastes in the blood, and a glomerular filtration rate (GFR) test to determine how well his or her kidneys filter waste from the body. Aside from the tests described, a kidney biopsy is also conducted to see if any IgA antibody is present in the glomerulus to aid the body in fighting this sickness.

The rising prevalence of chronic glomerular diseases and the increasing unmet need for treatments are primarily driving the IgA nephropathy (IgAN) market. In addition to this, the widespread adoption of supportive measures, including lifestyle modification such as dietary sodium and protein restriction, smoking cessation, weight control, exercise as appropriate, etc., for effective management of the disease is also acting as another growth-inducing factor. Moreover, several key players are making significant investments in clinical trials for a better understanding of the disease pathophysiology and developing IgAN therapies for slowing the disease progression and managing symptoms such as high blood pressure, protein in the urine, swelling, etc. This, in turn, is further creating a positive outlook for the market. Apart from this, the governing agencies of various countries, along with non-governmental organizations (NGOs), are encouraging numerous health education campaigns to generate awareness regarding the risk associated with liver-related disorders, such as IgA nephropathy, thereby augmenting the global market. Several other factors, including a robust pipeline with novel therapeutic targets and the identification of novel biomarkers for better diagnosis as well as disease progression monitoring, are expected to drive the global IgA nephropathy market (IgAN) in the coming years.

IMARC Group's new report provides an exhaustive analysis of the IgA nephropathy (IgAN) market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for igA nephropathy (IgAN)  and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the IgA nephropathy (IgAN) market in any manner.

Time Period of the Study

  • Base Year: 2022
  • Historical Period: 2017-2022
  • Market Forecast: 2023-2033
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the igA nephropathy (IgAN) market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the igA nephropathy (IgAN) market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

This report also provides a detailed analysis of the current igA nephropathy (IgAN) marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Regulatory Status
     

Key Questions Answered in this Report

Market Insights

  • How has the igA nephropathy (IgAN) market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
  • What was the country-wise size of the igA nephropathy (IgAN) market across the seven major markets in 2022 and what will it look like in 2033?
  • What is the growth rate of the igA nephropathy (IgAN) market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the size of the igA nephropathy (IgAN) patient pool (2017-2022) across the seven major markets?
  • What would be the forecasted patient pool (2023-2033) across the seven major markets?
  • What are the key factors driving the epidemiological trend of igA nephropathy (IgAN) ?
  • What will be the growth rate of patients across the seven major markets?
     

IgA Nephropathy (IgAN): Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for igA nephropathy (IgAN)  drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the igA nephropathy (IgAN) market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
IgA Nephropathy (IgAN) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033
Select Licence Type



Benefits of Customization

Personalize This Research

Triangulate with your Data

Get Data as per your Format and Definition

Gain a Deeper Dive into a Specific Application, Geography, Customer or Competitor

Any level of Personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Clients Testimonial

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Bayer AH

It was indeed a great experience to work with IMARC on the assignment on Aqua market. The team had done a fantastic job in terms of what was expected, what was assured and what was the result… the report gave us many insights and market know how which allowed us to work on our strength and define exact strategies…

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More